Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00286806 · ClinicalTrials.gov registry record · Phase 1
A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer
A Phase 1 study, sponsored by Ascenta Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00286806 is a Phase 1 study that has completed, run by Ascenta Therapeutics. The registered enrollment target is 27 participants.
The verdict
NCT00286806, a Phase 1 study, has completed, sponsored by Ascenta Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of single-agent AT-101 in men with hormone-refractory prostate cancer.
Interventions
- DRUG AT-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00286806
The ClinicalTrials.gov registry entry for NCT00286806 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ascenta Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AT-101 is the first listed.
NCT00286806 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00286806 about?
NCT00286806 is a clinical study titled "A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer". This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of single-agent AT-101 in men with hormone-refractory prostate cancer.
What is the current status of trial NCT00286806?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2005-12. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00286806?
The interventions under investigation include: AT-101 (DRUG).
Who is sponsoring clinical trial NCT00286806?
This trial is sponsored by Ascenta Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.